Therapies that aim to suppress ACTH and its actions are being pursued, including monoclonal antibodies against ACTH (14) and CRH receptor 1 antagonists with the latter in clinical trials for the treatment of ACTH-driven androgen excess in CAH (15). The gene discussed is POMC; the disease is hyperandrogenism.